Effects of local hypothermia-rewarming on physiology, metabolism and inflammation of acutely injured human spinal cord. by Gallagher, MJ et al.
1Scientific RepoRtS |         (2020) 10:8125  | https://doi.org/10.1038/s41598-020-64944-y
www.nature.com/scientificreports
Effects of local hypothermia–
rewarming on physiology, 
metabolism and inflammation of 
acutely injured human spinal cord
Mathew J. Gallagher1, Florence R. A. Hogg1, Siobhan Kearney1, Marcel A. Kopp2,3, 
Christian Blex2, Leonarda Serdani2, Oliver Sherwood1, Jan M. Schwab2,4, Argyro Zoumprouli5, 
Marios C. Papadopoulos1,6 & Samira Saadoun1,6 ✉
In five patients with acute, severe thoracic traumatic spinal cord injuries (TSCIs), American spinal 
injuries association Impairment Scale (AIS) grades A–C, we induced cord hypothermia (33 °C) then 
rewarming (37 °C). A pressure probe and a microdialysis catheter were placed intradurally at the injury 
site to monitor intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP), tissue metabolism and 
inflammation. Cord hypothermia–rewarming, applied to awake patients, did not cause discomfort or 
neurological deterioration. Cooling did not affect cord physiology (ISP, SCPP), but markedly altered 
cord metabolism (increased glucose, lactate, lactate/pyruvate ratio (LPR), glutamate; decreased 
glycerol) and markedly reduced cord inflammation (reduced IL1β, IL8, MCP, MIP1α, MIP1β). Compared 
with pre-cooling baseline, rewarming was associated with significantly worse cord physiology 
(increased ICP, decreased SCPP), cord metabolism (increased lactate, LPR; decreased glucose, glycerol) 
and cord inflammation (increased IL1β, IL8, IL4, IL10, MCP, MIP1α). The study was terminated because 
three patients developed delayed wound infections. At 18-months, two patients improved and three 
stayed the same. We conclude that, after TSCI, hypothermia is potentially beneficial by reducing 
cord inflammation, though after rewarming these benefits are lost due to increases in cord swelling, 
ischemia and inflammation. We thus urge caution when using hypothermia–rewarming therapeutically 
in TSCI.
Hypothermia is being investigated as a potential therapy for traumatic brain injury (TBI)1 and traumatic spinal 
cord injury (TSCI)2 based on compelling evidence from several laboratories and animal species that hypothermia 
is neuroprotective. In animal models of TBI, hypothermia has been shown to target many pathological pro-
cesses including reducing the metabolic rate, inflammation, edema, oxidative stress, excitotoxicity, electrolyte 
imbalance as well as apoptotic and necrotic cell death in vulnerable tissue3–8. Despite the encouraging findings of 
animal studies, randomized controlled human trials have failed to show functional benefit of hypothermia in TBI 
patients1,9,10. Therapeutic hypothermia is also beneficial in animal models of TSCI: rodent models of TSCI show 
improved histological and functional outcomes after hypothermia11,12. Small, non-randomized studies of TSCI 
patients also suggest improved functional outcomes after local13,14 or systemic hypothermia2,15. To date, there are 
no published randomized controlled trials of hypothermia for TSCI.
Despite the wide interest in therapeutic hypothermia for CNS injuries, there is paucity of mechanistic data 
from humans regarding the effect of hypothermia on the injury site. In TSCI patients, the effect of cooling and 
rewarming on cord swelling, metabolism and inflammation are unknown. It is thus unclear if hypothermia and 
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rewarming have beneficial or adverse effects on the injured human spinal cord. The lack of mechanistic informa-
tion from TSCI patients is due to the lack of advanced monitoring from the injury site. Our group has developed 
techniques to monitor intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP) and tissue metabolism 
from the injury site16–23. Here, we applied our monitoring techniques to define the effect of local hypothermia and 
rewarming on injury site physiology, metabolism and inflammation in TSCI patients.
Methods
Institutional research board approvals. The procedures followed were in accordance with the ethical 
standards of the responsible committee on human experimentation (institutional and national) and with the 
Helsinki Declaration of 1975, as revised in 2000 (World Medical Association Declaration of Helsinki 2000). 
Hypothermia–rewarming was approved as a sub-study (Amendment 7) of the ISCoPE (Injured Spinal Cord 
Pressure Evaluation) study for TSCI. Written consent was obtained from all patients. The hypothermia study, 
including the patient information sheet and the consent form, was approved by the St George’s, University of 
London Joint Research Office and the National Research Ethics Service London–St Giles committee (no. 10/
H0807/23). ISCoPE is registered as NCT02721615 at UK Clinical trials gateway since 01/09/2010 and at 
ClinicalTrials.gov since 29/03/2016. The study protocol, patient consent form, patient information sheet and 
Amendment 7 are enclosed.
Inclusion/exclusion criteria. This prospective patient cohort was recruited between September 2016 
and February 2017. Inclusion criteria were: (1) Severe TSCI defined as American spinal injuries association 
Impairment Scale (AIS) grade A, B, or C; (2) Age 18–70 years; (3) Surgery within 72 hours of TSCI; (4) Thoracic 
injury (we excluded cervical injuries because of the length of the cooling balloon). Exclusion criteria were: (1) 
Other major co-morbidities or concurrent injuries; (2) Penetrating TSCI; (3) No consent.
Clinical assessments and investigations. Examinations were performed according to the International 
Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) on admission, before discharge to 
the spinal rehabilitation facility (4–8 weeks) and during outpatient follow-ups (6–29 months). The patients were 
assessed by a neurosurgical TSCI research fellow trained in the ISNCSCI examination. CT and MRI scans of 
the whole spine were obtained on admission, a post-operative CT was done at 24–48 hours after surgery and 
a post-operative MRI after probe removal. On the Neuro-Intensive Care Unit (NICU), core temperature was 
recorded continuously from a urinary catheter temperature probe.
Spinal fixation. Surgery was done posteriorly and aimed to restore the normal spinal alignment with lami-
nectomies for bony decompression. Pedicle screws were inserted two levels above and two levels below the frac-
ture and were linked with rods secured with blockers, using the Xia 3 system (Stryker, Newbury, UK).
ISP probe and microdialysis catheter. An ISP probe (Codman Microsensor Transducer, Depuy Synthes, 
Leeds, UK) and a MD catheter (CMA 61, CMA microdialysis AB, Sweden) were tunnelled through the skin into 
the wound cavity. Under the operating microscope, the dura and arachnoid were opened one level below the 
injury. The ISP probe and MD catheter were inserted through the durotomy and advanced on the cord surface 
until the tips were at the site of maximal cord swelling. The dural opening was sutured and supplemented with 
Tisseel (Baxter, UK). The ISP probe and MD catheter were sutured to the skin. These techniques are described in 
detail in our earlier publications16–23.
Cooling catheter. A sterile cooling balloon, part of a closed catheter loop system (Cool line catheter, Zoll 
medical, Cheshire, UK), and sterile thermometer (Smiths Medical, Ashford, UK) were tunnelled into the wound 
cavity and placed extradurally. A wound drain was inserted for a week and was set ‘under gravity’. The wound was 
closed in layers using vicryl sutures with nylon sutures for the skin. We gave 5,000 units dalteparin daily, starting 
at 24 hours after surgery. Dalteparin was omitted at 24 hours before and at 6 hours after removing the probes and 
wound drain. Prophylactic intravenous vancomycin/gentamicin were administered for 48 hours as per hospital 
protocol. In NICU, the wound was covered with an electric warming blanket set at 37 °C (CosyTherm mattress, 
Inspiration healthcare, Rotherham, UK).
Monitoring setup. The ISP probe was connected to a Codman ICP box linked by a ML221 amplifier to 
a PowerLab running LabChart software (version 7.3.5; ADInstruments). Arterial blood pressure was recorded 
from a radial artery catheter connected to the Philips Intellivue MX800 bedside monitoring system (Philips, 
Guildford, UK) in turn connected to the PowerLab system. ISP and arterial blood pressure signals were sam-
pled at 1 kHz for 7 days. LabChart was used to analyze the signals and compute SCPP, defined as MAP minus 
ISP. We previously showed that ISP measured this way is different from intrathecal pressure measured above or 
below the injury site because the swollen, injured cord is compressed against the surrounding dura thus com-
partmentalising the intrathecal space18,22,23. MD monitoring was started postoperatively in the NICU. CNS per-
fusion fluid (CMA Microdialysis AB, Sweden) was perfused at 0.3 µL/min using the CMA106 infusion pump 
(CMA Microdialysis AB, Sweden). MD vials were changed hourly and stored at 4 °C. The first two samples from 
each patient were discarded to allow priming of the MD catheter and stabilization of metabolite concentrations. 
Samples were batch-analyzed up to 24 hours later using ISCUS Flex (CMA Microdialysis AB, Sweden) for glu-
cose, lactate, pyruvate, glycerol, glutamate and lactate-to-pyruvate ratio (LPR). 100-fold changes in metabolite 
concentration, and 10-fold changes in LPR, compared with the preceding hour, were excluded. We previously 
showed that our MD method measures injury site surface metabolism, which correlates well with intraparen-
chymal metabolism (r = 0.56–0.91), but differs from metabolites measured from the lumbar cerebrospinal fluid 
(CSF) (r = 0.23–0.50)16–18.
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Cytokines/chemokines. We measured the concentrations of cytokines/chemokines in the MD fluid col-
lected from the injury site. These molecules were selected because they have been implicated in the pathophysiol-
ogy of spinal cord injury (see supplement), they are <30 kDa (i.e. can cross the MD membrane) and they are part 
of our multiplex electrochemiluminescence assay panel. For each patient, MD vials were grouped by sampling 
period: 6 hours pre-cooling, 6 hours at 33 °C and 6 hours post-rewarming i.e. at 37 °C. MD vials, each containing 
about 10 μL, were stored at −80 °C and analyzed in a blinded fashion at Charité-Universitätsmedizin Berlin by 
multiplex electrochemiluminescence assays (Meso Scale Discovery, Rockville, MD, USA) using the following 
antibody sets from the U-PLEX Biomarker Group 1 Human Assays panel (K15067L): IL1α, IL1β, IL4, IL8, IL10, 
IP10, GROα, MCP1, MIP1α, MIP1β. If necessary, the MD samples were diluted to the minimum required vol-
ume for a single determination (25 µl) or analyzed directly according to the manufacturer’s protocol. 96-well 
plates including samples, blanks and recombinant standard concentrations were measured and unknown con-
centrations calculated, using the MESO QuickPlex SQ 120 Reader and the MSD DISCOVERY WORKBENCH 
software version 4.0 (Meso Scale Discovery, Rockville, MD, USA), respectively.
Cooling-rewarming. A closed temperature system pumping sterile saline into the balloon catheter 
(Thermoguard XP temperature management system, Zoll Medical, Cheshire, UK) was connected at the bedside 
in NICU. Cooling was started at 12 hours after surgery, thus allowing baseline cord physiological and MD meas-
urements to be obtained. In the first patient, the target temperature was reduced by 1 °C every 12 hours (37 to 
33 °C). This slow reduction allowed real-time analysis of microdialysis samples and repeat neurological examina-
tions to ensure no deterioration. After 12 hours at 33 °C, the cord was rewarmed to 37 °C at 0.5 °C/hour. In sub-
sequent patients, the cord was cooled to 33 °C in one step and, after 72 hours, rewarmed at 0.5 °C/hour to 37 °C.
Data analysis and statistics. For ISP, SCPP and metabolites, we compared the 12 values at 37 °C imme-
diately preceding hypothermia (taken hourly) vs. the 12 values at 33 °C (taken hourly) vs. the first 12 values at 
37 °C i.e. post-rewarming (taken hourly). For cytokines/chemokines, we compared the 6 values at 37 °C imme-
diately preceding hypothermia (taken hourly) vs. 6 values at 33 °C (taken hourly) vs. the first 6 values at 37 °C 
i.e. post-rewarming (taken hourly). In each case, the three temperature groups (pre-hypothermia, hypother-
mia, post-rewarming) were compared pairwise by Kruskal-Wallis + post-hoc Dunn-Bonferroni. Analysis was 
done using XLStat Biomed version 2018.1 for Mac (Addinsoft, Paris, France). Statistical significance was taken 
as P < 0.05.
Results
Patient details. We recruited five consecutive patients with severe thoracic TSCIs (Fig. 1). Most were young 
(aged 45.4 ± 7.1 years, mean ± standard error) and male (66.7%). The delay between TSCI and surgery was 
47.4 ± 9.6 hours and the injury to cooling time 70.4 ± 9.3 hours. At 18.2 ± 5.1 months follow up, total motor score 
increased by 8.8 ± 8.5, total pin prick score by 6.8 ± 6.5 and total light touch score by 2.6 ± 2.5 points. Overall, 
two patients (40%) had improved by at least one AIS grade. For further details see Table 1 and Fig. 1a. Subsequent 
analysis includes all patients.
Cooling–rewarming. Local hypothermia and rewarming were well tolerated without causing pain, discom-
fort or shivering. Throughout the cooling and rewarming phases, all patients remained alert, orientated and 
self-ventilating with no changes in their neurological examinations. Details of our setup for cooling–rewarming 
and monitoring are shown in Fig. 1b,c. Except for the first patient (PT 49), who was subjected to a slow cooling 
protocol for safety, all subsequent patients reached the target extradural temperature of 33 °C in 20 minutes. In all 
patients, the cooling protocol reduced the extradural temperature to the target value without causing a significant 
change in the core temperature (Fig. 2).
Injury site physiology. In the 12 hours before the start of the cool–rewarm protocol, baseline spinal cord 
ISP was 12.7 mmHg and SCPP at 83.3 mmHg with MAP at 93.1 mmHg. Cooling from 37 to 33 °C did not pro-
duce any significant changes in ISP, SCPP or MAP. Rewarming from 33 to 37 °C was associated with significant 
increase in ISP by 13.2 mmHg and significant decrease in SCPP by 14.6 mmHg compared with corresponding 
average pre-cooling baseline levels, whereas MAP remained unaffected. For further details see Fig. 3.
Injury site metabolism. In the 12 hours before the start of the cool-rewarm protocol, baseline spinal cord 
tissue glucose concentration was 2.3 mM, tissue lactate 5.1 mM, tissue pyruvate 148.5 μM, tissue LPR 33.9, tissue 
glutamate 10.9 μM and tissue glycerol 54.5 μΜ. Cooling and rewarming had a major impact on injury site metab-
olism. Cooling was associated with significant increase in tissue glucose by 1.0 mM, significant increase in lactate 
by 1.9 mM, no change in pyruvate, significant increase in LPR by 113.0, significant increase in glutamate by 6.4 
μM and significant decrease in glycerol by 13.4 μM. Compared with average pre-cooling baseline levels, rewarm-
ing was associated with significant decrease in tissue glucose by 0.9 mM, significant increase in lactate by 3.9 mM, 
no change in pyruvate, significant increase in LPR by 314.9, no change in glutamate by 6.4 μM and significant 
decrease in glycerol by 30.0 μM. For details see Fig. 4.
Injury site inflammation. In the 12 hours before the start of the cool-rewarm protocol, baseline spinal 
cord IL1α concentration was 5.6 pg/mL, tissue IL1β was 13.5 pg/mL, tissue IL8 was 2,013.9 pg/mL, tissue IL4 
was 0.3 pg/mL, tissue IL10 was 1.0 pg/mL, tissue IP10 was 66.4 pg/mL, tissue MCP1 was 1,821.5 pg/mL, tissue 
MIP1α was 67.0 pg/mL, tissue MIP1β was 111.2 pg/mL and tissue GROα was 268.8 pg/mL. The concentrations of 
injury site inflammatory cytokines significantly decreased with cooling by 62.8% for IL1β, 87.1% for IL8, 58.7% 
for MCP1, 69.8% for MIP1α and 37.0% for MIP1β. Compared with hypothermia, there was rebound significant 
increase in the concentrations of inflammatory cytokines on rewarming by 465 .3% for IL1β, 606.1% for IL8, 
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241.6% for IL4, 848.1% for IL10 and 222.4 for MIP1α. A markedly, though statistically non-significant rise in 
cytokine/chemokine concentration after rewarming was also observed for IL1α, IP10, and GROα. Compared 
with baseline, after rewarming the levels of IL1α, IL1β, IL4, IL10, IP10, MIP1β and GROα were higher whereas 
the levels of IL8, MCP1 and MIP1α were lower; these changes were not significant except for MCP1. For details 
see Fig. 5.
Complications. Spinal cord cooling and rewarming was associated with complications, summarized in 
Table 2. In 1/5 (20%) patients, the equipment failed; there was a hole in the cooling catheter balloon that allowed 
the cooled sterile saline fluid to enter the wound cavity and leave through the wound drain. In this patient, 
cooling was stopped and the catheter was removed. Three of the five (60%) patients had culture positive delayed 
wound infections; in two of the three patients, we performed wound washout under general anesthetic. These 
three patients received antibiotics with the metalwork in situ and recovered with no deterioration in ISNCSCI 
neurological scores. In contrast, we have reported no wound infections in 42 consecutive patients that had spinal 
cord monitoring without hypothermia21. After discussion with the sponsors was well as our neurosurgical, inten-
sive care unit and microbiology colleagues, the decision was taken to prematurely terminate the study.
Outcomes. At a mean follow-up of 36 weeks, 2/5 (40%) patients improved AIS grade, one from A to B and 
the other from B to D. We observed increase in mean ISNCSCI total motor score by 8.8 points (0–39), pin prick 
Figure 1. Setup. (a) Sagittal T2 pre-operative spinal MRI of the five patients (ISCoPE No. 49, 51, 53, 55, 57). 
Label shows fractured vertebra. (b) Schematic of setup for monitoring and cooling produced using Canvas 
Draw 3 for MacOS, https://www.canvasgfx.com/en/products/canvas-draw/. ISP probe and microdialysis 
catheter lie intradurally, on the surface of the injured cord. Cooling catheter and thermometer are extradural. 
A heating pad is placed on the skin. (c) Post-operative spinal CT showing ISP probe, microdialysis (MD) and 
cooling catheters.
PT Age Sex
Injury to 
surgery 
(hours)
Injury to 
cooling 
(hours)
Injury 
level
Admission Followup
Followup 
(months)AIS TMS TPP TLT AIS TMS TPP TLT
49 66 F 65 88 T3 B 50 54 54 D 89 83 61 29
51 36 M 49 71 T5 A 50 52 52 A 50 48 48 25
53 30 M 21 45 T6 A 50 52 52 A 50 52 52 22
*55 52 F 36 60 L1 A 51 81 80 B 56 88 88 6
57 43 M 66 88 T3 A 50 40 40 A 50 42 42 9
Table 1. Demographics of the five patients in the study. F, Female; M, Male; AIS, American spinal injuries 
association Impairment Scale; PT, patient; TLT, total light touch score; TMS, total motor score; TPP, total pin 
prick score; *No cooling, equipment failure.
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sensation of 6.8 points (−4–29) and total light touch sensation of 2.6 points (−4–8). The wounds appeared 
well-healed at follow-up.
Discussion
We employed local hypothermia aiming to avoid the side effects of systemic hypothermia i.e. coagulopathy, elec-
trolyte disturbances, myocardiac ischemia, atrial fibrillation, sepsis, pneumonia and altered drug metabolism24. 
Our key findings are that, during hypothermia–rewarming in awake TSCI patients, there is no discomfort or shiv-
ering and no change in ISNCSCI motor and sensory scores. The hypothermia phase was potentially beneficial, by 
reducing injury site inflammation, though during the rewarming phase these benefits were lost due to rebound 
increases in injury site swelling, ischemia and inflammation. The study was terminated early because of delayed 
wound infections in 60% of patients. The major weaknesses of our study are the small sample size and the lack of 
a control group.
In a previous study of local hypothermia, cooling was induced within 7 hours of TSCI at a rapid rate using an 
extradural device set at 6 °C; hypothermia lasted 3–4 hours with rapid rewarming13. In comparison, we started 
hypothermia later on, cooled within 20 min (apart from the first patient) to 33 °C for 12 hours and rewarmed 
slowly at 0.5 °C/h. It has been suggested that slower rewarming (<0.5 °C/h) might be more beneficial25. We do 
not know whether earlier onset hypothermia or more prolonged hypothermia or slower rewarming might have 
shown beneficial effects on ISP, SCPP, cord metabolism and cord inflammation. Because our study was termi-
nated early; we were unable to study the effects of these changes on the injured spinal cord.
Hypothermia had no significant impact on baseline ISP, whereas rewarming was associated with a marked 
rebound rise in ISP by 13.2 mmHg. Since the MAP remained constant throughout, the ISP rise caused a marked 
drop in SCPP by 14.6 mmHg. These findings mirror observations in human TBI, where hypothermia caused 
non-significant decrease in intracranial pressure (ICP)9,10 and rewarming caused rebound rise in ICP26. The effects 
of hypothermia–rewarming on ICP may be related to blood flow changes, i.e. vasoconstriction during hypother-
mia and vasodilatation during rewarming27. In our patients, baseline ISP was not elevated, at 12.7 mmHg, which 
may explain why hypothermia did not reduce ISP. The ISP rise we observed after rewarming may have been 
caused by increased inflammation within the injured cord related to reperfusion. There is substantial evidence 
that during reperfusion, leukocytes become activated to release multiple inflammatory factors28, consistent with 
the marked rise in the tissue cytokines/chemokine levels observed here.
Hypothermia was associated with a rise in tissue glucose, lactate and LPR without change in pyruvate. 
Rewarming was associated with a marked fall in tissue glucose, rise in lactate and LPR, again with constant pyru-
vate. Hypothermia is known to reduce cellular metabolism and, in brain, for every 1 °C drop in temperature, there 
is a 6% drop in cerebral metabolic rate, which is expected to reduce glucose consumption at the injury site27, thus 
explaining the rise in tissue glucose concentration. After rewarming, the cord tissue glucose level fell probably due 
to increased cellular utilisation. In the brain, lactate is not only a by-product of anaerobic metabolism, but may 
Figure 2. Relations between various temperatures. (a) Extradural cool/rewarm regime. (b) Core temperature at 
target extradural temperatures 33 and 37 °C. (c) Actual extradural temperature at target extradural temperatures 
33 and 37 °C. (b,c) Show raw data and mean. Not significant ns, P < 0.0001††.
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also be a neuronal energy substrate29. Several mechanisms may thus account for the rise in tissue lactate, without 
change in tissue pyruvate, during hypothermia and rewarming e.g. depleted O2 supply thus increased anaerobic 
metabolism, failure of pyruvate dehydrogenase thus diverting pyruvate to lactate rather than into the tricarboxylic 
acid cycle and increased uptake of lactate at the injury site from the circulation. The relative contributions of these 
mechanisms may differ in hypothermia vs. rewarming. Whatever the underlying mechanisms, the main finding 
here is that hypothermia–rewarming is associated with a marked impairment of metabolism at the injury site.
Hypothermia–rewarming was also associated with rise in tissue glutamate and fall in tissue glycerol. 
Glutamate is an excitatory amino acid that causes excitotoxic damage to neurons, whereas glycerol is released 
Figure 3. Effect of cooling-rewarming on ISP, MAP and SCPP. (a) ISP, (b) MAP and (c) SCPP for 12 h before 
start of cooling (white, Pre), for 12 h at minimum temperature (gray, 33 °C) and for 24 h after the end of 
rewarming (black, Post). Mean + /− standard error. Not significant, ns; P < 0.0001††.
Figure 4. Effect of cooling-rewarming on injury site metabolites. (a) Glucose, (b) Lactate, (c) Pyruvate, (d) 
Lactate-to-pyruvate ratio (LPR), (e) Glutamate and (f). Glycerol. Metabolite levels for 12 h before start of 
cooling (white, Pre), for 12 h at minimum temperature (gray, 33 °C) and for 24 h after the end of rewarming 
(black, Post). Mean + /− standard error. ns not significant, P < 0.05*, <0.001##, <0.0001††.
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into the extracellular fluid during plasma cell membrane lysis30. Interestingly, during the 12 hours before the onset 
of hypothermia, tissue glutamate was rising at a rate of 1.3 μM/h, whereas glycerol was decreasing at a rate of 2.6 
μM/h. One possibility, therefore, is that changes in tissue glutamate and glycerol largely represent trends related 
to the timing from the injury rather than the effects of hypothermia or rewarming. In human TBI, hypothermia–
rewarming is generally associated with reduced ventricular CSF glutamate31. Other possibilities to explain our 
observation of increased MD glutamate during hypothermia in TSCI are lack of strong correlation between CSF 
vs. MD glutamate, as we have recently shown32, or even differences in the cell-level responses to traumatic injury 
of the spinal cord compared with the brain33.
A striking finding in our study is the marked reduction in the concentrations of tissue cytokines/chemok-
ines during hypothermia followed by rebound enhancement of tissue inflammation associated with rewarm-
ing, generally to above pre-hypothermia baselines. Several cell types likely secrete cytokines at the injury site 
including neutrophils, macrophages, microglia, lymphocytes, astrocytes and endothelial cells. The differential 
responses of these cytokines to hypothermia-rewarming may be due to differential responses of these cell types 
to hypothermia-rewarming. The effect of hypothermia in suppressing inflammation after TSCI mirrors findings 
in animal models34 though the effect of rewarming on inflammation has not been investigated. On the one hand, 
the suppression of inflammation induced by hypothermia may be beneficial to the damaged spinal cord, but on 
the other hand it may predispose to wound infection. An earlier study reported a wound infection rate of 10%13 
and our study found 60% wound infection rate. Potential ways to reduce wound infection risk in future trials 
Figure 5. Effect of cooling-rewarming on injury site inflammatory mediators. (a) IL1α, (b) IL1β, (c) IL8, (d) 
IL4, (e) IL10, (f) IP10, (g) MCP1, (h) MIP1α, (i) MIP1β and (j). GROα. Mediator levels for 12 h before start 
of cooling (white, Pre), for 12 h at minimum temperature (gray, 33 °C) and for 24 h after the end of rewarming 
(black, Post). Mean + /- standard error. Not significant ns, P < 0.05*, <0.005#, <0.001##.
Patient
Wound 
breakdown
Wound 
bacteria
Surgical wound 
treatment Antibiotics Outcome
49 Yes E. coli S. aureus
Day 16 lumbar 
drain Day 43 
debridement
52 days Wound well-healed
51 No No No No Wound well-healed
53 No E. coli No 45 days Wound well-healed
*55 No No No No Wound well-healed
57 Yes S. aureus
Day 22 pus 
aspirated Day 24 
debridement
56 days Wound well-healed
Table 2. Wound complications of localized hypothermia. *No cooling, equipment failure.
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include prolonged antibiotics and iodine impregnated occlusive dressings. The rebound increase in tissue inflam-
mation is potentially detrimental to the injured cord e.g. by increasing vasogenic edema from breakdown of the 
blood-spinal cord barrier28.
Based on our findings here, we urge caution when performing trials of hypothermia for TSCI without simulta-
neously monitoring from the injury site to determine in real time the impact on the injured spinal cord.
Data availability
All data generated or analyzed during this study are included in this published article.
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